Cambrex is a global contract development and manufacturing organization (CDMO) focused on small‑molecule pharmaceuticals. The company provides drug substance and drug product services, including development, scale‑up, and cGMP manufacturing of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms for pharmaceutical and biotechnology customers. It operates a network of facilities in North America and Europe.
Capabilities span process and analytical development, route design and optimization, solid‑state and formulation development, high‑potency handling, and clinical to commercial manufacturing, supported by quality and regulatory expertise. Cambrex works across the small‑molecule lifecycle to help transition programs from early development through validated commercial supply.
chemXplore tracks 1 project involving Cambrex.
Cambrex's role on them: Owner.
The Karlskoga facility now has new reactors and a continuous flow unit, boosting production efficiency and flexibility for high purity intermediates, with completion expected by Q3 2017.
By country, the most active first. active / all projects
